

4th Annual Jefferson Liver Disease Symposium
Saturday, March 24, 2018
Thomas Jefferson University · Philadelphia, PA

2018 Course Learning Objectives:

At the conclusion of this activity, participants should be able to:

- Identify and appraise the new and emerging innovative drug treatments for the management of chronic hepatitis C infection and appreciate further advancements in the field over the past 12 months.
- Develop an understanding on current FDA-approved drugs for treating hepatitis B as well as new, novel agents in the pipeline.
- Discuss and analyze the novel approaches to treating patients with nonalcoholic steatohepatitis and explore the multiple therapeutic pathways under investigation.
- Describe the diagnostic criteria for autoimmune hepatitis and also recognize how these patients are treated.
- Review the treatment armamentarium for managing HCC based on disease stage.
- Describe the differential diagnosis of unique liver disorders affecting pregnant women.
- Appreciate the role of cross-sectional imaging in diagnosing liver disorders and understand what is meant by “LIRADS”.
- Appreciate the new name and new FDA-approved therapy for the cholestatic liver disease, PBC, and explore new advancements in managing PSC.
- Recognize the diagnostic evaluation of a liver transplant candidate in assessing their comorbid risk for surgery. Appreciate how we diagnose PPHTN, HPS and how sarcopenia contributes to operative risk.
- Understand the management approach and differential diagnosis to allograft dysfunction in the first 12 months post-OLT.
- Appreciate the role of the transplant hepatologist in conducting comprehensive long-term care of the liver transplant recipient, to effect the best possible survival.
- Assess their individual practice in light of the information and discussions during the course, and identify specific strategies to implement as part of a continuing improvement process for their practices.